Douglas Holtzman - Feb 13, 2023 Form 4 Insider Report for Icosavax, Inc. (ICVX)

Role
Chief Scientific Officer
Signature
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
Stock symbol
ICVX
Transactions as of
Feb 13, 2023
Transactions value $
-$50,338
Form type
4
Date filed
2/15/2023, 07:07 PM
Previous filing
Dec 16, 2022
Next filing
Feb 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ICVX Common Stock Sale -$16.3K -1.52K -0.52% $10.69 293K Feb 13, 2023 Direct F1, F2
transaction ICVX Common Stock Sale -$34.1K -3.35K -1.14% $10.17 290K Feb 14, 2023 Direct F3, F4
holding ICVX Common Stock 2.79K Feb 13, 2023 By Stanley Holtzman F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the applicable withholding taxes upon settlement of restricted stock units issued to the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.41 to $11.02. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 8, 2022.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.83 to $10.72. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 Douglas Holtzman, Ph.D. holds power-of-attorney (POA) over the shares owned by Stanley Holtzman. As POA, Dr. Holtzman holds voting and dispositive control over such shares. Dr. Holtzman disclaims beneficial ownership of the shares over which he has POA except to the extent of any pecuniary interest therein.